Overview / Abstract: |
STATEMENT OF NEED Hematopoietic stem cell transplant is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow transplant in older patients and alternative graft sources that afford a donor for nearly all patients who require a transplant. Despite these advances, studies continue to show that the use of HSCT remains suboptimal, placing many patients at increased risk for poor survival outcomes. TARGET AUDIENCE Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients eligible for HSCT. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1. Assess the susceptibility of hematologic malignancies to the graft-versus-leukemia effects of HSCT Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians. |
Expiration |
Jul 25, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.25 AMA PRA Category 1 Credit(s) / 1.2 ANCC Contact Hours |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Miguel-Angel Perales, MD (Chairperson) |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from Sanofi Genzyme and Incyte. |
Keywords / Search Terms |
i3 Health i3 Health, HSCT, stem cell transplant, hematology, oncology, oncology CME, oncology CE, free CME, free CE, ILNA points Free CE CME |